Erasca (ERAS) EBITDA (2020 - 2026)
Erasca posted quarterly EBITDA of -$184.8 million for Q1 2026, down 501.01% year-on-year from $46.1 million in Q1 2025, and down 534.65% on a QoQ basis from -$29.1 million in Q4 2025.
Erasca (ERAS) has 7 years of EBITDA data on file, last reported at -$184.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 501.01% year-over-year to -$184.8 million; the trailing twelve-month figure through Mar 2026 stood at -$278.3 million (down 77.56% YoY), and the FY2025 full-year result was -$124.3 million, up 22.93% from the prior year.
- EBITDA for Q1 2026 stood at -$184.8 million, down from -$29.1 million in the prior quarter.
- Across five years, EBITDA topped out at -$29.0 million in Q4 2023 and bottomed at -$184.8 million in Q1 2026.
- The 5-year median for EBITDA is -$33.7 million (2024), against an average of -$49.3 million.
- The widest annual swing landed in 2023, when EBITDA jumped 78.47%; it then plunged 501.01% in 2026.
- A 5-year view of EBITDA shows it stood at -$134.9 million in 2022, then surged by 78.47% to -$29.0 million in 2023, then decreased by 15.85% to -$33.7 million in 2024, then grew by 13.49% to -$29.1 million in 2025, then plunged by 534.65% to -$184.8 million in 2026.
- The last three EBITDA figures came in at -$184.8 million (Q1 2026), -$29.1 million (Q4 2025), and -$30.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -184.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -184.77 Mn |
| Dec 31, 2025 | -29.11 Mn |
| Sep 30, 2025 | -30.38 Mn |
| Jun 30, 2025 | -34.09 Mn |
| Mar 31, 2025 | -30.74 Mn |
| Dec 31, 2024 | -33.65 Mn |
| Sep 30, 2024 | -29.18 Mn |
| Jun 30, 2024 | -63.19 Mn |
| Mar 31, 2024 | -35.30 Mn |
| Dec 31, 2023 | -29.05 Mn |
| Sep 30, 2023 | -30.14 Mn |
| Jun 30, 2023 | -32.06 Mn |
| Mar 31, 2023 | -32.67 Mn |
| Dec 31, 2022 | -134.91 Mn |
| Sep 30, 2022 | -35.65 Mn |
| Jun 30, 2022 | -35.88 Mn |
| Mar 31, 2022 | -37.25 Mn |
| Dec 31, 2021 | -30.63 Mn |
| Sep 30, 2021 | -46.07 Mn |
| Jun 30, 2021 | -28.22 Mn |
| Mar 31, 2021 | -18.02 Mn |
| Dec 31, 2020 | -61.90 Mn |
| Sep 30, 2020 | -10.61 Mn |
| Jun 30, 2020 | -5.48 Mn |